Continuous monitoring of clinical distribution and drug resistance of Proteus mirabilis

Objective To assess the variations of clinical distribution and drug resistance of Proteus mirabilis and to provide reference for clinical selection of antibiotics.Methods The bacteria were identified by VITEK-2 and PHEONIX system.Antibiotic sensitivity test was conducted with Kirby-Bauer method and automatic machine.The data were analyzed by WHONET 5.4 software.Results There were 844 isolates of Proteus mirabilis during the 10 year's monitoring,with 304 from urine(36.0%),263 from sputum(31.2%),and 176 from secretion(20.9%).The rate of extended-spectrum β-lactamases(ESBLs)production was 45.6%,57.0%,and 37.2% for the isolates in 2008,2009,and 2010,respectively.The drug resistance rate of Proteus mirabilis to cephalosporin increased with the time and the rate to carbapenem was 3.0%.The resistance rate to quinolones obviously increased after 2005.Conclusion The drug resistance rate to quinolones and cephalosporin increased in recent years but carbapenem and enzymeinhibitor still maintain well antimicrobial activity to Proteus mirabilis.